Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
3 competitors in Diabetes Mellitus
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Zynquista
Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ? 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.
View on EMAInfluenza (Healthy Volunteers)
Type 2 Diabetes Mellitus
Diphtheria
Non Small Cell Lung Cancer
Influenza